Archive · 21 Jan 2026
Moderna Shifts Focus to Cancer and Personalized Medicine
Moderna, the company known for its COVID-19 vaccines, is now focusing on fighting cancer and creating personalized medicines.
Their CEO, Stéphane Bancel, said they are moving into a new phase where they will use mRNA technology to develop treatments for various cancers.
They have already shown promising results in skin cancer and are working on treatments for lung, stomach, kidney, and bladder cancers.
Moderna is also using artificial intelligence to speed up the development of these new medicines.
They plan to launch these cancer treatments by 2027 and are looking to expand their operations globally, including in India.
Additionally, they are developing combination vaccines for flu and COVID-19 to improve vaccination rates.
Moderna is shifting its focus from COVID-19 vaccines to oncology and personalized mRNA medicines.
The company has shown a 50% improvement in recurrence-free survival in skin cancer trials with Merck.
Moderna plans to launch cancer treatments by 2027 and is exploring expansion into India.
AI is being used to accelerate drug development and regulatory processes.
The company expects to return to sales growth and diversify away from COVID-19 by 2026.
- Who
- Moderna, led by CEO Stéphane Bancel
- What
- Shift from COVID vaccines to oncology and personalized medicine
- When
- Expected commercial launch of cancer treatments by 2027
- Where
- Global expansion, including potential operations in India
- Why
- To diversify revenue streams and leverage mRNA technology for cancer treatments
- Company
- Moderna
- CEO
- Stéphane Bancel
- Current Products
- 3 approved globally, 2 more expected in 2024
- New Focus Areas
- Oncology, personalized mRNA medicines, preventive vaccines
- Key Partnership
- Merck for skin cancer treatment
- AI Application
- Accelerating drug development and regulatory timelines
- Future Goals
- Commercial launch of cancer treatments by 2027, expansion in India